Introduction: The α subunit of voltage-gated sodium channels in mammals is encoded by 9 different genes, and variations in the SCN1A, SCN2A, SCN3A, and SCN8A genes highly expressed in the CNS have been associated with epilepsy phenotypes. This study aimed at investigating the frequency of SCN1A gene variations in Dravet syndrome (DS) and GEFS+ spectrum phenotype cases and discussing the molecular results in the context of genotype-phenotype correlation. Methods: Fifteen patients diagnosed with DS and 54 patients meeting the GEFS+ spectrum criteria were included in this study. All patients were evaluated by next-generation sequencing and multiplex ligation-dependent probe amplification using an SCN1A gene commercial kit. Results: A total of 17 different variants were detected in 18 index cases (26%), of which 7 were novel variations (p.M1R, p.M147T, p.I767L, p.N1391Ifs*5, p.R1886G, p.E1915G, p.R1933Q). Of the 18 cases with variation in the SCN1A gene, 12 had DS and 6 had GEFS+ phenotype. The variations were de novo in all DS cases and in 1 case with a GEFS+ phenotype; in 5 GEFS+ cases, the variant was inherited from the affected parent. Discussion: This study contributes to the variation spectrum in cases with DS and GEFS+ phenotype with the novel variants detected. SCN1A genetic analysis can help in determining whether antiseizure medication should be selected or avoided in cases with variations. The elucidation of the molecular etiology makes it possible to provide the family with effective genetic counseling for future pregnancies.

1.
Bayat
A
,
Hjalgrim
H
,
Møller
RS
.
The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009
.
Epilepsia
.
2015
;
56
:
e36
9
.
2.
Bayat
A
,
Bayat
M
,
Rubboli
G
,
Møller
RS
.
Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy
.
Genes (Basel)
.
2021
;
12
(
7
):
1051
.
3.
Ceulemans
BP
,
Claes
LR
,
Lagae
LG
.
Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy
.
Pediatr Neurol
.
2004
;
30
:
236
43
.
4.
Cho
MJ
,
Kwon
SS
,
Ko
A
,
Lee
ST
,
Lee
YM
,
Kim
HD
,
Efficacy of Stiripentol in Dravet Syndrome with or without SCN1A Mutations
.
J Clin Neurol
.
2018
;
14
(
1
):
22
8
.
5.
Claes
L
,
Del-Favero
J
,
Ceulemans
B
,
Lagae
L
,
Van Broeckhoven
C
,
De Jonghe
P
.
De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy
.
Am J Hum Genet
.
2001
;
68
:
1327
32
.
6.
de Lange
IM
,
Koudijs
MJ
,
van 't Slot
R
,
Gunning
B
,
Sonsma
ACM
,
van Gemert
LJJM
,
Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes
.
Epilepsia
.
2018
;
59
(
3
):
690
703
.
7.
de Lange
IM
,
Mulder
F
,
van 't Slot
R
,
Sonsma
ACM
,
van Kempen
MJA
,
Nijman
IJ
,
Modifier genes in SCN1A-related epilepsy syndromes
.
Mol Genet Genomic Med
.
2020
;
8
(
4
):
e1103
.
8.
Depienne
C
,
Trouillard
O
,
Saint-Martin
C
,
Gourfinkel-An
I
,
Bouteiller
D
,
Carpentier
W
,
Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients
.
J Med Genet
.
2009
;
46
(
3
):
183
91
.
9.
Dichgans
M
,
Freilinger
T
,
Eckstein
G
,
Babini
E
,
Lorenz-Depiereux
B
,
Biskup
S
,
Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine
.
Lancet
.
2005
;
366
(
9483
):
371
7
.
10.
Dravet
C
.
The core Dravet syndrome phenotype
.
Epilepsia
.
2011
;
52
(
Suppl 2
):
3
9
.
11.
Dravet
C
,
Bureau
M
,
Oguni
H
,
Fukuyama
Y
,
Cokar
O
.
Severe myoclonic epilepsy in infancy: Dravet syndrome
.
Adv Neurol
.
2005
;
95
:
71
102
.
12.
Escayg
A
,
Goldin
AL
.
Sodium channel SCN1A and epilepsy: mutations and mechanisms
.
Epilepsia
.
2010
;
51
:
1650
8
.
13.
Escayg
A
,
Heils
A
,
MacDonald
BT
,
Haug
K
,
Sander
T
,
Meisler
MH
.
A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus -- and prevalence of variants in patients with epilepsy
.
Am J Hum Genet
.
2001
;
68
:
866
73
.
14.
Fan
C
,
Wolking
S
,
Lehmann-Horn
F
,
Hedrich
UB
,
Freilinger
T
,
Lerche
H
,
Early-onset familial hemiplegic migraine due to a novel SCN1A mutation
.
Cephalalgia
.
2016
;
36
(
13
):
1238
47
.
15.
Fujiwara
T
.
Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies
.
Epilepsy Res
.
2006
;
70 Suppl 1
:
S223
30
.
16.
Fukuma
G
,
Oguni
H
,
Shirasaka
Y
,
Watanabe
K
,
Miyajima
T
,
Yasumoto
S
,
Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB)
.
Epilepsia
.
2004
;
45
(
2
):
140
8
.
17.
Goldberg-Stern
H
,
Aharoni
S
,
Afawi
Z
,
Bennett
O
,
Appenzeller
S
,
Pendziwiat
M
,
Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus
.
J Child Neurol
.
2014
;
29
:
221
6
.
18.
Guerrini
R
,
Oguni
H
.
Borderline Dravet syndrome: a useful diagnostic category?
Epilepsia
.
2011
;
52
(
Suppl 2
):
10
2
.
19.
Harkin
LA
,
McMahon
JM
,
Iona
X
,
Dibbens
L
,
Pelekanos
JT
,
Zuberi
SM
,
The spectrum of SCN1A-related infantile epileptic encephalopathies
.
Brain
.
2007
;
130
:
843
52
.
20.
Helbig
I
.
Genetic Causes of Generalized Epilepsies
.
Semin Neurol
.
2015
;
35
(
3
):
288
92
.
21.
Herini
ES
,
Gunadi
,
Harahap
IS
,
Yusoff
S
,
Morikawa
S
,
Patria
SY
,
Generalized epilepsy with febrile seizures plus (GEFS+) spectrum: clinical manifestations and SCN1A mutations in Indonesian patients
.
Epilepsy Res
.
2010
;
90
(
1-2
):
132
9
.
22.
Heyne
HO
,
Baez-Nieto
D
,
Iqbal
S
,
Palmer
DS
,
Brunklaus
A
,
May
P
,
Predicting functional effects of missense variants in voltage-gated sodium and calcium channels
.
Sci Transl Med
.
2020
;
12
(
556
):
eaay6848
. .
23.
Ishii
A
,
Watkins
JC
,
Chen
D
,
Hirose
S
,
Hammer
MF
.
Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome
.
Epilepsia
.
2017
;
58
:
282
90
.
24.
Jaimes
A
,
Guerrero-López
R
,
González-Giráldez
B
,
Serratosa
JM
.
De novo truncating mutation in SCN1A as a cause of febrile seizures plus (FS+)
.
Epileptic Disord
.
2020
;
22
:
323
6
.
25.
Kalume
F
,
Yu
FH
,
Westenbroek
RE
,
Scheuer
T
,
Catterall
WA
.
Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy
.
J Neurosci
.
2007
;
27
:
11065
74
.
26.
Kang
KW
,
Kim
W
,
Cho
YW
,
Lee
SK
,
Jung
KY
,
Shin
W
,
Genetic characteristics of non-familial epilepsy
.
PeerJ
.
2019
;
7
:
e8278
.
27.
Kivity
S
,
Oliver
KL
,
Afawi
Z
,
Damiano
JA
,
Arsov
T
,
Bahlo
M
,
SCN1A clinical spectrum includes the self-limited focal epilepsies of childhood
.
Epilepsy Res
.
2017
;
131
:
9
14
.
28.
Kopanos
C
,
Tsiolkas
V
,
Kouris
A
,
Chapple
CE
,
Albarca Aguilera
M
,
Meyer
R
,
VarSome: the human genomic variant search engine
.
Bioinformatics
.
2019
;
35
:
1978
80
.
29.
Larsen
J
,
Carvill
GL
,
Gardella
E
,
Kluger
G
,
Schmiedel
G
,
Barisic
N
,
The phenotypic spectrum of SCN8A encephalopathy
.
Neurology
.
2015
;
84
:
480
9
.
30.
Malo
MS
,
Blanchard
BJ
,
Andresen
JM
,
Srivastava
K
,
Chen
XN
,
Li
X
,
Localization of a putative human brain sodium channel gene (SCN1A) to chromosome band 2q24
.
Cytogenet Cell Genet
.
1994
;
67
:
178
86
.
31.
Musto
E
,
Gardella
E
,
Møller
RS
.
Recent advances in treatment of epilepsy-related sodium channelopathies
.
Eur J Paediatr Neurol
.
2020
;
24
:
123
8
.
32.
Myers
CT
,
Hollingsworth
G
,
Muir
AM
,
Schneider
AL
,
Thuesmunn
Z
,
Knupp
A
,
Parental Mosaicism in "De Novo" Epileptic Encephalopathies
.
N Engl J Med
.
2018
;
378
:
1646
8
.
33.
Myers
KA
,
Burgess
R
,
Afawi
Z
,
Damiano
JA
,
Berkovic
SF
,
Hildebrand
MS
,
De novo SCN1A pathogenic variants in the GEFS+ spectrum: Not always a familial syndrome
.
Epilepsia
.
2017
;
58
:
e26
e30
.
34.
Myers
KA
,
Scheffer
IE
,
Berkovic
SF
,
ILAE Genetics Commission
.
Genetic literacy series: genetic epilepsy with febrile seizures plus
.
Epileptic Disord
.
2018
;
20
:
232
8
.
35.
O'Reilly
H
,
Eltze
C
,
Bennett
K
,
Verhaert
K
,
Webb
R
,
Merrett
A
,
Cognitive outcomes following epilepsy in infancy: A longitudinal community-based study
.
Epilepsia
.
2018
;
59
:
2240
8
.
36.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
,
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
.
Genet Med
.
2015
;
17
:
405
24
.
37.
Rochtus
AM
,
Goldstein
RD
,
Holm
IA
,
Brownstein
CA
,
Pérez-Palma
E
,
Haynes
R
,
The role of sodium channels in sudden unexpected death in pediatrics
.
Mol Genet Genomic Med
.
2020
;
8
:
e1309
.
38.
Rubinstein
M
,
Westenbroek
RE
,
Yu
FH
,
Jones
CJ
,
Scheuer
T
,
Catterall
WA
.
Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome
.
Neurobiol Dis
.
2015
;
73
:
106
17
.
39.
Scheffer
IE
,
Berkovic
SF
.
Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes
.
Brain
.
1997
;
120(Pt 3)
:
479
90
.
40.
Scheffer
IE
,
Nabbout
R
.
SCN1A-related phenotypes: Epilepsy and beyond
.
Epilepsia
.
2019
;
60 Suppl 3
:
S17
24
.
41.
Scheffer
IE
,
Zhang
YH
,
Jansen
FE
,
Dibbens
L
.
Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?
Brain Dev
.
2009
;
31
:
394
400
.
42.
Scheffer
IE
,
Berkovic
S
,
Capovilla
G
,
Connolly
MB
,
French
J
,
Guilhoto
L
,
ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology
.
Epilepsia
.
2017
;
58
:
512
21
.
43.
Shi
X
,
Yasumoto
S
,
Nakagawa
E
,
Fukasawa
T
,
Uchiya
S
,
Hirose
S
.
Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome
.
Brain Dev
.
2009
;
31
:
758
62
.
44.
Stenson
PD
,
Mort
M
,
Ball
EV
,
Chapman
M
,
Evans
K
,
Azevedo
L
,
The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting
.
Hum Genet
.
2020
;
139
:
1197
207
.
45.
Tan
EH
,
Razak
SA
,
Abdullah
JM
,
Mohamed Yusoff
AA
.
De-novo mutations and genetic variation in the SCN1A gene in Malaysian patients with generalized epilepsy with febrile seizures plus (GEFS+)
.
Epilepsy Res
.
2012
;
102
:
210
5
.
46.
Thompson
CH
,
Porter
JC
,
Kahlig
KM
,
Daniels
MA
,
George
AL
 Jr
.
Nontruncating SCN1A mutations associated with severe myoclonic epilepsy of infancy impair cell surface expression
.
J Biol Chem
.
2012
;
287
:
42001
8
.
47.
Trimmer
JS
,
Rhodes
KJ
.
Localization of voltage-gated ion channels in mammalian brain
.
Annu Rev Physiol
.
2004
;
66
:
477
519
.
48.
Vahedi
K
,
Depienne
C
,
Le Fort
D
,
Riant
F
,
Chaine
P
,
Trouillard
O
,
Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations
.
Neurology
.
2009
;
72
:
1178
83
.
49.
Verheyen
K
,
Wyers
L
,
Del Felice
A
,
Schoonjans
AS
,
Ceulemans
B
,
Van de Walle
P
,
Independent walking and cognitive development in preschool children with Dravet syndrome
.
Dev Med Child Neurol
.
2021
;
63
:
472
9
.
50.
Wallace
RH
,
Hodgson
BL
,
Grinton
BE
,
Gardiner
RM
,
Robinson
R
,
Rodriguez-Casero
V
,
Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms
.
Neurology
.
2003
;
61
:
765
9
.
51.
Wu
YW
,
Sullivan
J
,
McDaniel
SS
,
Meisler
MH
,
Walsh
EM
,
Li
SX
,
Incidence of Dravet Syndrome in a US Population
.
Pediatrics
.
2015
;
136
:
e1310
15
.
52.
Zaman
T
,
Helbig
KL
,
Clatot
J
,
Thompson
CH
,
Kang
SK
,
Stouffs
K
,
SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation
.
Ann Neurol
.
2020
;
88
:
348
62
.
53.
Zhang
YH
,
Burgess
R
,
Malone
JP
,
Glubb
GC
,
Helbig
KL
,
Vadlamudi
L
,
Genetic epilepsy with febrile seizures plus: Refining the spectrum
.
Neurology
.
2017
;
89
:
1210
9
.
54.
Zuberi
SM
,
Brunklaus
A
,
Birch
R
,
Reavey
E
,
Duncan
J
,
Forbes
GH
.
Genotype-phenotype associations in SCN1A-related epilepsies
.
Neurology
.
2011
;
76
:
594
600
.
55.
Zucca
C
,
Redaelli
F
,
Epifanio
R
,
Zanotta
N
,
Romeo
A
,
Lodi
M
,
Cryptogenic epileptic syndromes related to SCN1A: twelve novel mutations identified
.
Arch Neurol
.
2008
;
65
(
4
):
489
94
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.